Publications by authors named "C E de Moor"

There is increasing interest in the use of home-based monitoring in people with chronic lung diseases to improve access to care, support patient self-management, and facilitate the collection of information for clinical care and research. However, integration of home-based monitoring into clinical and research settings requires careful consideration of test performance and other attributes. There is no published guidance from professional respiratory societies to advance the science of home-based monitoring for chronic lung disease.

View Article and Find Full Text PDF

Complications like acute cellular rejection (ACR) and infection are known risk factors for the development of chronic lung allograft dysfunction, impacting long-term patient and graft survival after lung transplantation (LTx). Differentiating between complications remains challenging and time-sensitive, highlighting the need for accurate and rapid diagnostic modalities. We assessed the ability of exhaled breath analysis using an electronic nose (eNose) to distinguish between ACR, infection, and mechanical complications in LTx recipients (LTR) presenting with suspected complications.

View Article and Find Full Text PDF
Article Synopsis
  • Patients with systemic sclerosis are at high risk for interstitial lung disease (ILD), which can lead to increased mortality, making early detection critical for better management and outcomes.
  • The DecreaSSc study, conducted in the Netherlands, involved eligible patients using home spirometry to monitor lung function weekly for a year, comparing these results with hospital tests.
  • The study aimed to determine how well home spirometry could identify a significant decline in lung function (≥5% decrease in forced vital capacity) and involved patient feedback throughout its design and execution.
View Article and Find Full Text PDF
Article Synopsis
  • Cordycepin, a compound being studied for cancer therapy, has various proposed mechanisms of action, but recent research suggests its active form is cordycepin triphosphate which inhibits gene expression triggered by growth factors.
  • The compound was found to block critical cell signaling pathways (PI3K/AKT/mTOR and MEK/ERK) in multiple cell lines, without needing to activate AMPK.
  • The action of cordycepin on the mTOR pathway occurs rapidly, within just 30 minutes, indicating a universal effect on growth factor signaling through a currently unidentified target molecule.
View Article and Find Full Text PDF

Comprehensive care integrates individual patient needs and is highly valued for patients with pulmonary fibrosis (PF). The importance of a patient-centered care approach is rooted in the unpredictable progressiveness of the disease course in PF. The respiratory impairment associated with PF has a major impact on the quality of life for both patients and their caregivers.

View Article and Find Full Text PDF